Jane Street Group LLC Invests $142,000 in PDL Biopharma (PDLI) Stock

Jane Street Group LLC purchased a new position in PDL Biopharma (NASDAQ:PDLI) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 51,972 shares of the biotechnology company’s stock, valued at approximately $142,000.

Other large investors have also recently bought and sold shares of the company. Cubist Systematic Strategies LLC grew its stake in PDL Biopharma by 64.0% in the third quarter. Cubist Systematic Strategies LLC now owns 49,062 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 19,144 shares in the last quarter. Spark Investment Management LLC acquired a new position in PDL Biopharma in the fourth quarter worth about $142,000. Teacher Retirement System of Texas grew its stake in PDL Biopharma by 312.9% in the fourth quarter. Teacher Retirement System of Texas now owns 52,122 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 39,499 shares in the last quarter. Paloma Partners Management Co grew its stake in PDL Biopharma by 151.6% in the fourth quarter. Paloma Partners Management Co now owns 78,394 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 47,239 shares in the last quarter. Finally, BTC Capital Management Inc. acquired a new position in PDL Biopharma in the fourth quarter worth about $252,000. Institutional investors and hedge funds own 91.40% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ PDLI opened at $2.90 on Monday. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 0.14. PDL Biopharma has a 52-week low of $2.01 and a 52-week high of $3.55. The stock has a market capitalization of $446.05, a price-to-earnings ratio of 4.60 and a beta of 0.37.

PDL Biopharma (NASDAQ:PDLI) last issued its earnings results on Thursday, March 8th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter. PDL Biopharma had a net margin of 34.60% and a return on equity of 12.03%. The firm had revenue of $68.04 million for the quarter. analysts anticipate that PDL Biopharma will post 0.3 EPS for the current fiscal year.

A number of equities analysts have issued reports on the stock. Zacks Investment Research raised shares of PDL Biopharma from a “hold” rating to a “buy” rating and set a $3.50 target price on the stock in a report on Wednesday, March 14th. BidaskClub raised shares of PDL Biopharma from a “sell” rating to a “hold” rating in a report on Friday, April 6th. Finally, TheStreet raised shares of PDL Biopharma from a “d+” rating to a “c-” rating in a report on Friday, March 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $3.50.

ILLEGAL ACTIVITY WARNING: This news story was reported by Week Herald and is the property of of Week Herald. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://weekherald.com/2018/04/23/jane-street-group-llc-invests-142000-in-pdl-biopharma-pdli-stock.html.

About PDL Biopharma

PDL BioPharma, Inc acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates in three segments: Income Generating Assets, Pharmaceutical, and Medical Devices.

Institutional Ownership by Quarter for PDL Biopharma (NASDAQ:PDLI)

Receive News & Ratings for PDL Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply